会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 7. 发明申请
    • Method and Apparatus for Estimating Patient Populations
    • 用于估计患者人群的方法和装置
    • US20110184761A1
    • 2011-07-28
    • US13013314
    • 2011-01-25
    • Shipeng YuBalaji KrishnapuramFarbod RahmanianFaisal Farooq
    • Shipeng YuBalaji KrishnapuramFarbod RahmanianFaisal Farooq
    • G06Q50/00
    • G06Q50/22G06Q50/24
    • The methods and apparatuses of the present invention provide for a continuous abstraction of randomly sampled patient data and shortened data processing cycle times when an accurate sample population size is unknown at the beginning of the sampling process. The present invention estimates an initial medical patient population size for the purpose of randomly sampling that population. The estimated population size is calculated based on historical patient population data and is corrected at the end of the sample time period. Under-sampling is remediated at the end of the sample time period, during which continuous sampling of the patient data is carried out to provide interim and immediately available sampled patient data. Criteria for medical patient population sizing and sampling are provided by health care organizations responsible for administrating health care quality improvement standards.
    • 本发明的方法和装置提供随机采样的患者数据的连续抽象,并且在采样过程开始时精确的样本群体大小未知时缩短数据处理周期时间。 本发明为了随机抽取该群体而估计初始医疗患​​者群体大小。 估计的人口数量是根据历史患者人口数据计算的,并在采样时间段结束时进行修正。 在采样时间段结束时补救欠采样,在此期间对患者数据进行连续采样,以提供临时和即时可用的采样患者数据。 卫生保健机构由负责管理保健质量改进标准的医疗机构提供医疗病人人数调查和抽样标准。
    • 10. 发明申请
    • Computerized Surveillance of Medical Treatment
    • 电脑化医疗监察
    • US20120041784A1
    • 2012-02-16
    • US13228661
    • 2011-09-09
    • Faisal FarooqRomer E. RosalesShipeng YuBalaji KrishnapuramBharat R. Rao
    • Faisal FarooqRomer E. RosalesShipeng YuBalaji KrishnapuramBharat R. Rao
    • G06Q50/24
    • G06Q50/24G16H10/20G16H50/70
    • Medical treatment is automatically surveyed. Drugs or other treatments may be monitored post-market. This surveillance may be accomplished in two ways: (1) Identify patients that potentially match templates consistent with possible adverse reactions, possibly including adverse reactions not associated with the treatment. Potentially, if the match is good enough, a single patient may be sufficient to raise an alert. Alternately, multiple patients partially matching a template may cause an alert. (2) Identify patient clusters with unusual patterns. Multiple patients associated with greater rates of adverse events or event severity not expected with the treatment are identified. The data for surveillance is acquired from multiple sources, so may be more comprehensive for early recognition of adverse effects. Data gathering and surveillance are computerized, so early, cost effective recognition may be more likely.
    • 医疗自动进行调查。 药物或其他治疗方法可能在市场后监测。 这种监测可以通过以下两种方式完成:(1)确定潜在匹配模板的患者与可能的不良反应一致,可能包括与治疗无关的不良反应。 潜在地,如果比赛足够好,单个病人可能足以提高警戒。 或者,多个部分匹配模板的患者可能会引起警惕。 (2)识别具有异常模式的患者集群。 确定与治疗无法预期的不良事件或事件严重程度相关的多个患者。 监测数据来自多个来源,因此可能会更加全面地早期识别不良反应。 数据收集和监控是电脑化的,所以早期,成本有效的识别可能更有可能。